A concentrated GLP‑1 theme: core in big drugmakers (with a “recent winners” tilt) plus small side bets in Costco and Sweetgreen. Eli Lilly is always held; the rest rotates among peers based on short-term performance.

It splits money into three buckets: 9% Costco, 12% Sweetgreen, and 79% drugmakers tied to GLP‑1 weight‑loss/diabetes drugs. Inside the 79%: 20% always goes to Eli Lilly. The other 80% is split equally across the best 4 of Sanofi, Lilly, Novo Nordisk, Merck, and AstraZeneca based on roughly the last 7 weeks of returns. It adjusts when leaders change or weights drift.

GLP-1 focused strategy offers diversified, low-beta exposure (~0.67) to pharma leaders with consumer bets, aiming for returns beyond the S&P. Note: out-of-sample results show drawdown risk and negative gains; upside hinges on regime shifts.